Acute Pain
Conditions
Keywords
Analytical, Diagnostic,Therapeutic Technique and Equipment, Anesthesia and Analgesia
Brief summary
This study is designed to assess and characterize the safety and tolerability profile of LIQ865A and LIQ865B formulations compared to diluent or aqueous bupivacaine hydrochloride when infiltrated into a defined area of the medial calf, and to characterize bupivacaine plasma pharmacokinetic (PK) and pharmacodynamic (PD) profiles after a single dose of LIQ865A or LIQ865B, and to determine the individual plasma concentration/time curves and mean PK parameters of each product.
Detailed description
Infiltration of an aqueous local anesthetic, for example, bupivacaine, into surgical sites at closure provides temporary analgesia, typically lasting up to 6 hours, and is one aspect of the multimodal approach to postsurgical analgesia or fast-track surgery. However, the limited duration of action of local anesthetics, even longer acting agents such as bupivacaine, result in patients who are likely to experience end of duration breakthrough pain before they are able to take or tolerate oral analgesics, thus necessitating the use of strong parenteral analgesics in the immediate postsurgical period. LIQ865A and LIQ865B are two distinct formulations of bupivacaine manufactured via Liquidia Technologies PRINT (Particle Replication In Non-wetting Templates), which Liquidia intends to pursue for product approval. Both formulations being tested have the potential for producing long-lasting control of post-surgical incisional pain.
Interventions
DRUGLIQ865A bupivacaine formulation
single subcutaneous injection in medial calf
DRUGLIQ865B bupivacaine formulation
single subcutaneous injection in medial calf
DRUGDiluent for LIQ865
Sterile diluent composed of 12.5mg/g sodium hyaluronate, 5.8mg/g sodium chloride, 1mg/g polysorbate 80, 6.1mg/g Tris base, in sterile water for injection - single subcutaneous injection
DRUG0.5% bupivacaine hydrochoride
single subcutaneous injection
Sponsors
Premier Research
Liquidia Technologies, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* provide written informed consent prior to enrollment * be a non-smoking male, American Society of Anesthesiologist (ASA) physical class 1 or 2 * have a BMI between 18.5 and 25 kg. inclusive, and a weight of at least 60 kg * be willing and able to participate for the duration of the study * be healthy on the basis of pre-study physical examination (PE), medical history review, vital signs, lab test results as specified in the protocol * negative urine drug test results * negative alcohol screening test * negative antibody test results for hepatitis B, hepatitis C, and HIV
Exclusion criteria
* allergic to bupivacaine, or other amide local anesthetics, or the excipients in the LIQ865 formulations or the diluent * has taken any concomitant medications or supplements for the 3 days prior to Day 0 * has been on blood thinner or medication affecting platelet formation for the 7 days prior to Day 0 * in the opinion of the investigator, is either a hyper or hypo-responder to screening sensitivity testing * has a history of moderate or severe renal or hepatic impairment, moderate or severe active hepatic disease, or any other clinically significant medical condition that may preclude safe study participation * has a clinically significant test result for any screening lab parameter * has a history or ECG screening documentation of a clinically meaningful conduction abnormality * has scarring, tattoos, infections, or other skin changes in the area of planned study medication injection * has known neurological disease or dysfunction (central or peripheral) that may interfere with assessments * is unable to adequately communicate with study staff, properly give informed consent, or otherwise comply with study procedures, particularly the ability to return for outpatient follow up visits * has participated in another interventional clinical study (investigational or marketed product) within the 30 days prior to Day 0.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Treatment Emergent Adverse Events (AEs) | 30 days | Safety assessments will include the incidence and severity of AEs during treatment and the follow-up period of the study |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetic - Area under the plasma concentration curve from time zero to Day 5 | Timepoints (draws) at 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24 hours and 2, 3, 4, 5 days after treatment | — |
| Pharmacokinetic - Cmax (ng/mL) | Timepoints (draws) at 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24 hours and 2, 3, 4, 5 days after treatment | Maximum plasma concentration over the entire sampling period, directly obtained from the experimental data of plasma concentration versus time curves, without interpolation. |
| Pharmacokinetic - Tmax (h) | Timepoints (draws) at 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24 hours and 2, 3, 4, 5 days after treatment | Time to reach maximum plasma concentration |
| Pharmacokinetic - t1/2 (h) | Timepoints (draws) at 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24 hours and 2, 3, 4, 5 days after treatment | Apparent terminal elimination half-life |
| Pharmacokinetic - CST1/2 (h) | Timepoints (draws) at 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24 hours and 2, 3, 4, 5 days after treatment | Context-sensitive half-time measured from Tmax to time for plasma concentration to reach half of Cmax following study medication injection. |
| Pharmacodynamic Response - Pain intensity (Numeric Rating Scale) with Short Tonic Heat Stimulus (STHS) testing at various time points | 1, 2, 12, 24, 48, 72, 96, and 120 hours | Testing done to calculate time-weighted Sum of Pain Intensity Differences (SPID) at the time points noted, compared to Baseline, and time specific SPID results |
| Pharmacodynamic Response - Change in Mechanical Pain Threshold (MPT) compared to Baseline using various time points | 12, 24, 48, 72, 96, and 120 hours | Calculate the time-weighted sum of threshold differences (calculated as area-under-the-curve (AUC): AUC12, AUC24, AUC48, AUC72, AUC96, AUC120 |
| Pharmacodynamic Response - Change in Heat Pain Threshold (HPT) compared to Baseline using various time points | 12, 24, 48, 72, 96, and 120 hours | Calculate the time-weighted sum of threshold differences (calculated as area-under-the-curve (AUC): AUC12, AUC24, AUC48, AUC72, AUC96, AUC120 |
| Pharmacodynamic Response - Change Mechanical Detection Threshold (MDT) compared to Baseline using various time points | 12, 24, 48, 72, 96, and 120 hours | Calculate the time-weighted sum of threshold differences (calculated as area-under-the-curve (AUC): AUC12, AUC24, AUC48, AUC72, AUC96, AUC120 |
| Pharmacodynamic Response - Change in Warmth Detection Threshold (WDT) compared to Baseline using various time points | 12, 24, 48, 72, 96, and 120 hours | Calculate the time-weighted sum of threshold differences (calculated as area-under-the-curve (AUC): AUC12, AUC24, AUC48, AUC72, AUC96, AUC120 |
| Pharmacodynamic Response - Change in Cold Detection Threshold (CDT) compared to Baseline using various time points | 12, 24, 48, 72, 96, and 120 hours | Calculate the time-weighted sum of threshold differences (calculated as area-under-the-curve (AUC): AUC12, AUC24, AUC48, AUC72, AUC96, AUC120 |
Countries
Denmark
Outcome results
None listed